Eugene serves as Co-Head of Healthcare Investment Banking and U.S. Head of Biotechnology and Specialty Pharmaceuticals, focused on mergers and acquisitions and capital raising transactions. He joined us in 2010 to enhance our emerging therapeutics sector focus, bringing over 19 years of significant life sciences investment banking experience at HSBC, Wells Fargo, and Robertson Stephens. He has advised clients on a wide variety of corporate finance and strategic assignments, including mergers & acquisitions, IPOs, public offerings and private placements of debt and equity securities, PIPEs and LBOs for both public and private companies. Eugene graduated from the Leonard N. Stern School of Business at New York University with an MBA and a degree in Biology from New York University.
Selected Transactions
-
US$295m
Intra-Cellular Therapies Inc.
Co-Lead Manager (Follow-on)
-
US$63m
Fibrocell
Sole Financial Advisor
-
US$70m
Selecta Biosciences
PIPE Lead Co-Placement Agent
-
US$74m
Aptose Biosciences Inc.
Bookrunner (Follow-on Offering)
-
US$65m
X4 Pharmaceuticals, Inc.
Co-Manager (Follow-on)
-
US$287m
ACADIA Pharmaceuticals
Co-Manager (Follow-on)
-
N/a
Rezolute
Lead Agent (PIPE)
-
US$150m
Atara Biotherapeutics, Inc.
Co-Manager (CMPO)
-
US$125m
Atreca Inc.
Lead Manager (IPO)